Johnson & Johnson's (JNJ) Q1: Worldwide Consumer sales -2.4% Y/Y to $3.6B, hurt by negative currency impact of 2.9%. Worldwide pharmaceutical sales +1.2% to $6.1B, led by strong international sales of Remicade. Worldwide Medical Devices and Diagnostics sales -0.3% to $6.4B. Sees FY12 EPS of $5.07-$5.17, above prior guidance of $5.05-$5.15. Shares +0.5% premarket
Goldman Sachs (GS): Cost-cutting is the key, with operating expenses off 14% Y/Y to $6.77B, led by compensation expenses -16% to $4.38B. Investment banking revenue off 9% Y/Y to $1.15B. Net revenue in FICC off 20% Y/Y to $3.46B. Net revenue in Investment Management off 8% to $1.18B. Shares -2.2% premarket.
TD Ameritrade (AMTD): FQ2 EPS of $0.25 misses by $0.01. Revenue of $673M (-6.3% Y/Y) in-line.
State Street (STT): Q1 EPS of $0.84 misses by $0.03. Revenue of $2.42B (+3% Y/Y) beats by $80M
More Stocks News
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/